New SGO 2026 data show frontline checkpoint inhibitors give 4-year survival boost and almost no relapses after two years in dMMR cancers

Data presented at the 2026 Society of Gynecologic Oncology meeting highlight the performance of frontline checkpoint inhibitor regimens in patients with deficient mismatch repair (dMMR) cancers.

The analysis reports a clear survival advantage, with patients experiencing four‑year overall survival gains compared with historical controls.

Importantly, the relapse rate drops to near zero after two years of treatment, suggesting durable disease control.

These findings reinforce the therapeutic value of checkpoint inhibition in the dMMR setting and may influence future treatment guidelines.